{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","spread":"0.0","upperLimit":"0.5","value":"0.5"}]}],"title":"Infants and Toddlers (age<2 years old; n=2)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","spread":"58.6","upperLimit":"4.1","value":"1.1"}]}],"title":"Children (age>=2 and <12 years old; n=43)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","spread":"82.2","upperLimit":"6.0","value":"1.0"}]}],"title":"Adolescents (age>=12 and <18 years old; n=28)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","spread":"NA","upperLimit":"0.9","value":"0.9"}]}],"title":"Above 18 Years (n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","spread":"70.9","upperLimit":"6.0","value":"1.0"}]}],"title":"Total (n=74)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.","dispersionType":"Full Range","groups":[{"description":"Stratum 1 (Ph+ CP-CML): Participants with imatinib-resistant Ph+ CML in CP; Stratum 2/3 (PH+ ALL OR AP/BP-CML): Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in AP, or in MBP, or in LBP; or relapsed or refractory Ph+ ALL after imatinib use; or second or subsequent relapse of Ph+ AML; Stratum 4 (PH- ALL/AML): Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Strata 1, 2/3, and 4: 60 mg/m\\^2 starting dose; 80 mg/m\\^2 escalated/dose level 2; Stratum 4: 100 mg/m\\^2 escalated/dose level 3 and 120 mg/m\\^2 escalated/dose level 4. QD, as long as clinical benefit was observed.","id":"OG000","title":"Dasatinib 60 mg/m^2 QD Starting Dose"}],"paramType":"MEDIAN","populationDescription":"All treated participants with plasma samples available. Each participant could have 1, 2, or 3 plasma PK profiles sampled, depending on the number of times the dose of dasatinib was escalated. n=number of PK parameters included.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) by Age Group","type":"SECONDARY","unitOfMeasure":"hours"}